Publication: Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
Issued Date
2013-02-01
Resource Type
ISSN
10985514
0022538X
0022538X
Other identifier(s)
2-s2.0-84873051328
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Virology. Vol.87, No.3 (2013), 1554-1568
Suggested Citation
Munir S. Alam, Hua Xin Liao, Georgia D. Tomaras, Mattia Bonsignori, Chun Yen Tsao, Kwan Ki Hwang, Haiyan Chen, E. Lloyd Krissey E., Cindy Bowman, Laura Sutherland, Thomas L. Jeffries, Daniel M. Kozink, Shelley Stewart, Kara Anasti, Frederick H. Jaeger, Robert Parks, Nicole L. Yates, Glenn R. Overman, Faruk Sinangil, Phillip W. Berman, Punnee Pitisuttithum, Jaranit Kaewkungwal, Sorachai Nitayaphan, Nicos Karasavva, Supachai Rerks-Ngarm, Jerome H. Kim, Nelson L. Michael, Susan Zolla-Pazner, Sampa Santra, Norman L. Letvin, Stephen C. Harrison, Barton F. Haynes Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. Journal of Virology. Vol.87, No.3 (2013), 1554-1568. doi:10.1128/JVI.00718-12 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/31077
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion
Author(s)
Munir S. Alam
Hua Xin Liao
Georgia D. Tomaras
Mattia Bonsignori
Chun Yen Tsao
Kwan Ki Hwang
Haiyan Chen
E. Lloyd Krissey E.
Cindy Bowman
Laura Sutherland
Thomas L. Jeffries
Daniel M. Kozink
Shelley Stewart
Kara Anasti
Frederick H. Jaeger
Robert Parks
Nicole L. Yates
Glenn R. Overman
Faruk Sinangil
Phillip W. Berman
Punnee Pitisuttithum
Jaranit Kaewkungwal
Sorachai Nitayaphan
Nicos Karasavva
Supachai Rerks-Ngarm
Jerome H. Kim
Nelson L. Michael
Susan Zolla-Pazner
Sampa Santra
Norman L. Letvin
Stephen C. Harrison
Barton F. Haynes
Hua Xin Liao
Georgia D. Tomaras
Mattia Bonsignori
Chun Yen Tsao
Kwan Ki Hwang
Haiyan Chen
E. Lloyd Krissey E.
Cindy Bowman
Laura Sutherland
Thomas L. Jeffries
Daniel M. Kozink
Shelley Stewart
Kara Anasti
Frederick H. Jaeger
Robert Parks
Nicole L. Yates
Glenn R. Overman
Faruk Sinangil
Phillip W. Berman
Punnee Pitisuttithum
Jaranit Kaewkungwal
Sorachai Nitayaphan
Nicos Karasavva
Supachai Rerks-Ngarm
Jerome H. Kim
Nelson L. Michael
Susan Zolla-Pazner
Sampa Santra
Norman L. Letvin
Stephen C. Harrison
Barton F. Haynes
Other Contributor(s)
Duke University School of Medicine
Global Solutions for Infectious Diseases
University of California, Santa Cruz
Mahidol University
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
Walter Reed Army Institute of Research
New York Harbor Healthcare System
NYU School of Medicine
Beth Israel Deaconess Medical Center
Children's Hospital Boston
Howard Hughes Medical Institute
Global Solutions for Infectious Diseases
University of California, Santa Cruz
Mahidol University
Armed Forces Research Institute of Medical Sciences, Thailand
Thailand Ministry of Public Health
Walter Reed Army Institute of Research
New York Harbor Healthcare System
NYU School of Medicine
Beth Israel Deaconess Medical Center
Children's Hospital Boston
Howard Hughes Medical Institute
Abstract
An immune correlates analysis of the RV144 HIV-1 vaccine trial revealed that antibody responses to the gp120 V1/V2 region correlated inversely with infection risk. The RV144 protein immunogens (A244-rp120 and MN-rgp120) were modified by an N-terminal 11-amino-acid deletion (δ11) and addition of a herpes simplex virus (HSV) gD protein-derived tag (gD). We investigated the effects of these modifications on gp120 expression, antigenicity, and immunogenicity by comparing unmodified A244 gp120 with both δ11 deletion and gD tag and with δ11 only. Analysis of A244 gp120, with or without δ11 or gD, demonstrated that the δ11 deletion, without the addition of gD, was sufficient for enhanced antigenicity to gp120 C1 region, conformational V2, and V1/V2 gp120 conformational epitopes. RV144 vaccinee serum IgGs bound more avidly to A244 gp120 δ11 than to the unmodified gp120, and their binding was blocked by C1, V2, and V1/V2 antibodies. Rhesus macaques immunized with the three different forms of A244 gp120 proteins gave similar levels of gp120 antibody titers, although higher antibody titers developed earlier in A244 δ11 gp120-immunized animals. Conformational V1/V2 monoclonal antibodies (MAbs) gave significantly higher levels of blocking of plasma IgG from A244 δ11 gp120-immunized animals than IgG from animals immunized with unmodified A244 gp120, thus indicating a qualitative difference in the V1/V2 antibodies induced by A244 δ11 gp120. These results demonstrate that deletion of N-terminal residues in the RV144 A244 gp120 immunogen improves both envelope antigenicity and immunogenicity. © 2013, American Society for Microbiology.